SPDL1 and melanoma: In any case, the fact that sPD-L1 has a detrimental role in the clinical outcome of melanoma patients treated with anti-CTLA4 [31] antibodies strongly suggests the existence of other mechanisms apart from a direct interaction between the soluble and membrane-bound forms in the context of ICI immunotherapy.